- Home
- ONVO
as 07-26-2024 4:00pm EST
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 10.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 166.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $2.05 | Next Earning Date: | 08-08-2024 |
| Revenue: | $109,000 | Revenue Growth: | -70.54% |
| Revenue Growth (this year): | 22.59% | Revenue Growth (next year): | 19.85% |
Latest Organovo Holdings Inc. News
ONVO Breaking Stock News: Dive into ONVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Zacks Small Cap Research
2 months ago
ONVO Increases Cash and Improves Prospects
GlobeNewswire
2 months ago
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
GlobeNewswire
2 months ago
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
GlobeNewswire
3 months ago
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Zacks Small Cap Research
3 months ago
ONVO Announces Very Positive Phase 2 Results
Reuters
3 months ago
Organovo's fatty liver disease drug meets main goal in mid-stage study
GlobeNewswire
3 months ago
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Compare ONVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONVO Organovo Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.